Business Description
Northwest Biotherapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US66737P6007
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.05 | |||||
Equity-to-Asset | -2.71 | |||||
Debt-to-Equity | -0.73 | |||||
Debt-to-EBITDA | -0.85 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -76.98 | |||||
Beneish M-Score | -4.22 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 58.9 | |||||
3-Year EPS without NRI Growth Rate | 22.9 | |||||
3-Year FCF Growth Rate | 1.3 | |||||
3-Year Book Growth Rate | 49.6 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.09 | |||||
Quick Ratio | 0.09 | |||||
Cash Ratio | 0.05 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 | |||||
Shareholder Yield % | -4.31 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -3779.64 | |||||
Net Margin % | -4479.03 | |||||
FCF Margin % | -3710.34 | |||||
ROA % | -254.79 | |||||
ROIC % | -128.47 | |||||
3-Year ROIIC % | -9.12 | |||||
ROC (Joel Greenblatt) % | -318.6 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 159.45 | |||||
EV-to-EBIT | -6.67 | |||||
EV-to-EBITDA | -6.87 | |||||
EV-to-Revenue | 274.02 | |||||
EV-to-FCF | -7.38 | |||||
Earnings Yield (Greenblatt) % | -14.99 | |||||
FCF Yield % | -15.35 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Northwest Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 1.305 | ||
EPS (TTM) (£) | -0.064 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (£) | 0 | ||
20-Day SMA (£) | 2.4 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (£) | 2.4 - 2.4 | ||
Shares Outstanding (Mil) | 1,248.24 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Northwest Biotherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Northwest Biotherapeutics Inc Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Northwest Biotherapeutics Inc Frequently Asked Questions
What is Northwest Biotherapeutics Inc(LTS:0K95)'s stock price today?
When is next earnings date of Northwest Biotherapeutics Inc(LTS:0K95)?
Does Northwest Biotherapeutics Inc(LTS:0K95) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |